158 related articles for article (PubMed ID: 1703129)
21. Establishment of three novel human malignant pleural mesothelioma cell lines: morphological and cytogenetical studies and EGFR mutation status.
Kobayashi M; Takeuchi T; Ohtsuki Y
Anticancer Res; 2008; 28(1A):197-208. PubMed ID: 18383846
[TBL] [Abstract][Full Text] [Related]
22. The cytologic diagnosis of mesothelioma.
Ehya H
Semin Diagn Pathol; 1986 Aug; 3(3):196-203. PubMed ID: 3616223
[TBL] [Abstract][Full Text] [Related]
23. The value of the immunoperoxidase slide assay in the diagnosis of malignant pleural effusions in breast cancer.
Guzman J; Costabel U; Bross KJ; Wiehle U; Grunert F; Schaefer HE
Acta Cytol; 1988; 32(2):188-92. PubMed ID: 3279712
[TBL] [Abstract][Full Text] [Related]
24. Cytology of experimental mesotheliomas induced with crocidolite asbestos.
Topov J; Kolev K
Acta Cytol; 1987; 31(3):369-73. PubMed ID: 3035848
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical properties of malignant mesothelioma cells in histologic and cytologic specimens.
Motoyama T; Watanabe T; Okazaki E; Tanaka N; Watanabe H
Acta Cytol; 1995; 39(2):164-70. PubMed ID: 7534025
[TBL] [Abstract][Full Text] [Related]
26. Long microvilli of mesothelioma are conspicuous in pleural effusions processed by Ultrafast Papanicolaou stain.
Yang GC
Cancer; 2003 Feb; 99(1):17-22. PubMed ID: 12589641
[TBL] [Abstract][Full Text] [Related]
27. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma.
Delahaye M; Hoogsteden HC; Van der Kwast TH
J Pathol; 1991 Oct; 165(2):137-43. PubMed ID: 1744800
[TBL] [Abstract][Full Text] [Related]
28. Atypical mesothelial cells associated with eosinophilic pleural effusions: nuclear DNA content and immunocytochemical staining reaction with epithelial markers.
Kobayashi TK; Gotoh T; Nakano K; Kanagawa Y; Kimura T; Sato T
Cytopathology; 1993; 4(1):37-46. PubMed ID: 7680909
[TBL] [Abstract][Full Text] [Related]
29. Establishment and characterization of three new breast-cancer cell lines.
Siwek B; Larsimont D; Lacroix M; Body JJ
Int J Cancer; 1998 May; 76(5):677-83. PubMed ID: 9610725
[TBL] [Abstract][Full Text] [Related]
30. The cytology of malignant mesothelioma in Western Australia.
Whitaker D; Shilkin KB
Acta Cytol; 1978; 22(2):67-70. PubMed ID: 276234
[TBL] [Abstract][Full Text] [Related]
31. Malignant mesothelioma: cytologic diagnosis with histologic, immunohistochemical, and ultrastructural correlation.
Leong AS; Stevens MW; Mukherjee TM
Semin Diagn Pathol; 1992 May; 9(2):141-50. PubMed ID: 1609156
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical panel for distinguishing between carcinoma and reactive mesothelial cells in serious effusions.
Lee JS; Nam JH; Lee MC; Park CS; Juhng SW
Acta Cytol; 1996; 40(4):631-6. PubMed ID: 8693877
[TBL] [Abstract][Full Text] [Related]
33. Serum-dependent growth patterns of two, newly established human mesothelioma cell lines.
Klominek J; Robért KH; Hjerpe A; Wickström B; Gahrton G
Cancer Res; 1989 Nov; 49(21):6118-22. PubMed ID: 2790824
[TBL] [Abstract][Full Text] [Related]
34. Karyotypic changes in the preclinical and subsequent stages of malignant mesothelioma: a case report.
Hansteen IL; Hilt B; Lien JT; Skaug V; Haugen A
Cancer Genet Cytogenet; 1993 Oct; 70(2):94-8. PubMed ID: 7694791
[TBL] [Abstract][Full Text] [Related]
35. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
36. Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis.
Orengo AM; Spoletini L; Procopio A; Favoni RE; De Cupis A; Ardizzoni A; Castagneto B; Ribotta M; Betta PG; Ferrini S; Mutti L
Eur Respir J; 1999 Mar; 13(3):527-34. PubMed ID: 10232421
[TBL] [Abstract][Full Text] [Related]
37. Asbestos-associated chromosomal changes in human mesothelial cells.
Lechner JF; Tokiwa T; LaVeck M; Benedict WF; Banks-Schlegel S; Yeager H; Banerjee A; Harris CC
Proc Natl Acad Sci U S A; 1985 Jun; 82(11):3884-8. PubMed ID: 2987952
[TBL] [Abstract][Full Text] [Related]
38. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.
Porcel JM; Vives M; Esquerda A; Salud A; Pérez B; Rodríguez-Panadero F
Chest; 2004 Dec; 126(6):1757-63. PubMed ID: 15596670
[TBL] [Abstract][Full Text] [Related]
39. [Pleural effusion cytology of asbestos-associated malignant mesothelioma and lung carcinoma in the diagnosis of occupational diseases by the statutory accident insurance funds].
Biesterfeld S; Schramm M; Schad A; Pomjanski N
Pneumologie; 2014 Apr; 68(4):270-6. PubMed ID: 24615665
[TBL] [Abstract][Full Text] [Related]
40. Ultrastructural studies of cells in body cavity effusions.
Bewtra C; Greer KP
Acta Cytol; 1985; 29(3):226-38. PubMed ID: 3859122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
